SAN FRANCISCO, CA — June 24, 2002 —
One 35 mg weekly dose of risedronate (Actonel) is as effective as 5 mg daily for reducing the risk of vertebral fracture in women with osteoporosis.
Investigators presented these findings here June 21st at ENDO 2002, the 84th annual meeting of the Endocrine Society.
Prior research had shown that both dosing regimens are comparably effective at increasing bone mineral density (BMD) and reducing bone remodelling.
However, the investigators of a trial evaluation the weekly dose could not assess anti-fracture efficacy due to the absence of a placebo group. “There is a dilemma in some trials because in certain circumstances it is considered unethical to have a placebo group from whom treatment is withheld,” said co-investigator Nelson B. Watts, MD, program director of the Bone Health and Osteoporosis Center at the University of Cincinnati, Ohio, United States. “Since risedronate has been proven to be effective, this is the case in osteoporosis trials involving this medication.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!